Kapil M.

I have been emphasized Top 10 indian org Ranking Pharma companies in india So as Top 15 Jewels indian Pharmaceutical companies Now let's see In Global Scenario what impact Top 10 Global Companies Scenario and their impact amongst Indian Pharmaceutical faternity and consumer based Activities. Top 10 Global Ranking Pharmaceutical Companies and Their Impact on Indian Pharma Fraternity 1. Pfizer: A global pharmaceutical giant, Pfizer has significantly influenced Indian healthcare through innovative therapies and landmark drugs. Its COVID-19 vaccine and products in cardiology, oncology, and antibiotics are widely used in India. Pfizer’s India operations also contribute to R&D and local clinical trials. 2. AbbVie: Known for its blockbuster biologic Humira, AbbVie has entered India with a strong focus on specialty care, especially in immunology and oncology. It has partnered with Indian firms for biosimilar development and collaborative clinical research. 3. Johnson & Johnson: With a diversified portfolio, J&J has impacted Indian healthcare via its consumer health, pharmaceuticals, and medical devices. Its manufacturing and training initiatives have improved surgical techniques and rural health services in India. 4. Merck & Co. (MSD): MSD’s India subsidiary plays a major role in expanding access to essential vaccines and chronic disease medications. Its programs for HPV awareness and diabetes management have created significant public health awareness. 5. Novartis: Novartis contributes to Indian pharma through novel therapies, strong investment in R&D, and its GBS center in Hyderabad. Its innovation in generics and biosimilars (through Sandoz) aligns well with India’s healthcare affordability goals. 6. Bristol Myers Squibb (BMS): Though niche-focused, BMS’s impact on India comes via partnerships in oncology and immunotherapy. Its research collaborations with Indian CROs and data science units support global trials and drug development. 7. Sanofi: Sanofi has a strong legacy in India in insulin, vaccines (Shantha Biotech), and rare disease therapy. It supports disease elimination programs and operates robust manufacturing and research facilities in Goa and Hyderabad. 8. AstraZeneca: AstraZeneca is actively involved in Indian clinical research, particularly in oncology and cardiovascular medicine. It has nurtured a robust scientific community by collaborating with Indian academic institutions. 9. Roche: Roche’s footprint in India includes advanced oncology therapies and diagnostics. Its emphasis on precision medicine and early disease detection has modernized oncology care in India. 10. GSK (GlaxoSmithKline): With over 90 years in India, GSK is integral to Indian pharma, especially in vaccines, respiratory care, and antibiotics. These global pharma leaders have transformed Indian healthcare through strategic alliances, research collaborations. #globalpharmaindiaimpact# #indianpharmaimporters# #globalindiahealthmission#

256

8 Comments

What a news today in Economic Times - Aurobindo Pharma has emerged as a frontrunner to acquire Prague-based generic drugmaker Zentiva from Advent International for an estimated $5-5.5 billion. It was never expected that this potential acquisition would be one of the largest pharma buyouts by an Indian company and would significantly strengthen Aurobindo's presence in the European market, particularly in Eastern Europe. This news has completely changed the perception of Aurobindo pharma.

1,986

31 Comments

💊 𝗢𝗻𝗲 𝗠𝗼𝗿𝗲 𝗮𝗻𝗱 𝗖𝗼𝘂𝗻𝘁𝗶𝗻𝗴: 𝗜𝗻𝗱𝗶𝗮’𝘀 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗚𝗶𝗮𝗻𝘁𝘀 𝗞𝗲𝗲𝗽 𝗠𝗮𝗸𝗶𝗻𝗴 𝗚𝗹𝗼𝗯𝗮𝗹 𝗠𝗼𝘃𝗲𝘀 AUROBINDO PHARMA LTD is reportedly closing in on a $5.5 billion acquisition of Zentiva – #Europe’s leading generics player. If successful, this will be the largest-ever pharma buyout by an Indian company, surpassing even Sun Pharma’s landmark Ranbaxy deal. This isn’t just another M&A headline. It reflects a larger story of Indian healthcare scaling globally: 🌍 Expanding footprints in Europe & beyond 📈 Growing consolidation of pharmaceutical assets 💰 Indian pharma’s rising appetite for big-ticket global acquisitions 𝗙𝗿𝗼𝗺 #𝗕𝗶𝗼𝗰𝗼𝗻 𝘁𝗼 #𝗦𝘂𝗻𝗣𝗵𝗮𝗿𝗺𝗮 𝘁𝗼 #𝗖𝗶𝗽𝗹𝗮 – 𝗮𝗻𝗱 𝗻𝗼𝘄 𝗔𝘂𝗿𝗼𝗯𝗶𝗻𝗱𝗼 – 𝗜𝗻𝗱𝗶𝗮𝗻 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗮𝗿𝗲 𝗿𝗲𝘄𝗿𝗶𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝘂𝗹𝗲𝘀 𝗼𝗳 𝗴𝗹𝗼𝗯𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗹𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽. 🚀 The boom is real. And it’s only the beginning. #Healthcare #MergersAndAcquisitions #Pharma #IndiaGrowthStory #Aurobindo #India Opulix Advisory Services

53

The US move to impose a 100% tariff on imported branded medicines is a challenge, but also an opportunity. In my latest The Economic Times article, I share how this shift could strengthen India’s manufacturing backbone, accelerate self-reliance, and push innovation in biologics, biosimilars, and advanced drug delivery systems. Read here: https://lnkd.in/ghfdbssP #IndianPharma #USTariff #GlobalHealthcare #Innovation #AffordableHealthcare #Policy

736

23 Comments

Mr. Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals, in exclusive interaction with Laxmi Yadav, PharmaClick shares key insights on the Arab region, innovation in pharma, and Akums’ role in strengthening global healthcare through compliance-led, scalable manufacturing. Read the full interview here: : https://lnkd.in/gMJZj9x3 #Akums #PharmaClick #GlobalHealthcare #PharmaLeadership

370

14 Comments

The USFDA isn’t a hurdle. It’s a growth strategy 📈 Every company dreads inspections. But here’s the truth: ▪️ The most resilient Indian pharma companies embrace the USFDA — and build to meet it. ▪️ A successful USFDA audit isn’t just a compliance win. It’s a passport to global trust, investor confidence, and long-term margins. Instead of fearing the regulator, let’s build for the world 🌍 That’s how Indian pharma scales.

79

9 Comments

Clinical trials are moving East. If India blinks, it could miss the decade’s biggest opening. Big statement, right? But hear this out first. In 2017, China initiated just over 600 clinical trials. Now the number has almost surged more than 2000, and that's not just incremental growth, it’s a strategic pivot. Having worked across so many global portfolios in the EU, LATAM and many more, I’ve seen how quickly momentum builds when regulation, infrastructure, and incentives align. Take the instance of China, which introduced policies like the 60-day “implied license” rule, joined the ICH, and built world-class trial ecosystems, all in under a decade. Today, nearly a quarter of global early drug development happens in China. And major pharma players are now in-licensing experimental molecules from Chinese labs at an unprecedented pace. That’s why at Pinnacle Life Science, we’re tracking this shift closely. Not out of concern, but out of conviction because India has every reason to lead in this new geography of innovation in #pharma. But it won’t happen by default. We need faster regulatory approvals, globally aligned clinical trial frameworks, and deeper investment in R&D infrastructure. India has the talent, the scale, and the scientific credibility. Now, it just needs the systems to match. #GlobalPharma #ResearchandDevelopment

59

2 Comments